No Benefit of Saxagliptin on Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Potential Explanations

被引：1
|
作者：
Jialal, Ishwarlal [1 ]
Dhindsa, Sandeep [2 ]
机构：
[1] Univ Calif Davis, Med Ctr, Lab Atherosclerosis & Metab Res, Sacramento, CA 95817 USA
[2] Texas Tech Univ, Hlth Sci Ctr, Div Endocrinol & Metab, Odessa, TX USA
来源：
METABOLIC SYNDROME AND RELATED DISORDERS | 2014年 / 12卷 / 03期
关键词：
DIPEPTIDYL PEPTIDASE-4 INHIBITORS; THERAPY;
D O I：
10.1089/met.2014.1500
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：157 / 158
页数：2
相关论文
共 50 条
  • [1] Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
    Scirica, Benjamin M.
    Bhatt, Deepak L.
    Braunwald, Eugene
    Steg, P. Gabriel
    Davidson, Jaime
    Hirshberg, Boaz
    Ohman, Peter
    Frederich, Robert
    Wiviott, Stephen D.
    Hoffman, Elaine B.
    Cavender, Matthew A.
    Udell, Jacob A.
    Desai, Nihar R.
    Mosenzon, Ofri
    McGuire, Darren K.
    Ray, Kausik K.
    Leiter, Lawrence A.
    Raz, Itamar
    Braunwald, Eugene
    Bhatt, Deepak L.
    Scirica, Benjamin M.
    Udell, Jacob A.
    Cavender, Matthew A.
    Desai, Nihar
    Abrahamsen, Timothy
    Grossman, Michelle
    Morin, Suzanne
    Im, Kyungah
    Hoffman, Elaine
    Gabovitch, Daniel
    Pricken, Alexandra
    Mosenzon, Ofri
    Buskila, Alona
    Ohman, Peter
    Hirshberg, Boaz
    Stahre, Christina
    Price, Deborah
    Billing-Clason, Solveig
    Sabel, Karin
    Monyak, John
    Sjostrand, Mikalea
    Wei, Cheryl
    Lu, Jane
    Miller, Elinor
    Raichlen, Joel
    Fitt, Sandy
    Frederich, Robert
    Iqbal, Nayyar
    Donovan, Mark
    Davidson, Jaime A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (14): : 1317 - 1326
  • [2] SAXAGLIPTIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES
    Raz, I
    Scirica, B. M.
    Braunwald, E.
    Mosenzon, O.
    Hirshberg, B.
    Wiviott, S. D.
    Frederich, R.
    Davidson, J.
    Leiter, L. A.
    Bhatt, D. L.
    HYPERTENSION, 2014, 63 (06) : E167 - E167
  • [3] Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
    Michael E Cobble
    Robert Frederich
    Cardiovascular Diabetology, 11
  • [4] Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
    Cobble, Michael E.
    Frederich, Robert
    CARDIOVASCULAR DIABETOLOGY, 2012, 11
  • [5] Saxagliptin (Onglyza) for Type 2 Diabetes Mellitus
    Whalen, Karen
    St Onge, Erin
    AMERICAN FAMILY PHYSICIAN, 2010, 81 (12) : 1483 - 1484
  • [6] Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
    Kapoor, Karan
    George, Praveen
    Miller, Michael
    CARDIOLOGY, 2016, 135 (02) : 108 - 126
  • [7] Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus
    Garnock-Jones, Karly P.
    DRUGS, 2017, 77 (03) : 319 - 330
  • [8] Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus
    Karly P. Garnock-Jones
    Drugs, 2017, 77 : 319 - 330
  • [9] A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
    Frederich, Robert
    Alexander, John H.
    Fiedorek, Fred T.
    Donovan, Mark
    Berglind, Niklas
    Harris, Susan
    Chen, Roland
    Wolf, Robert
    Mahaffey, Kenneth W.
    POSTGRADUATE MEDICINE, 2010, 122 (03) : 16 - 27
  • [10] Saxagliptin: A guide to its use in type 2 diabetes mellitus
    Lyseng-Williamson K.A.
    Yang L.P.H.
    Drugs & Therapy Perspectives, 2014, 30 (3) : 92 - 99
12345